British Journal of Dermatology · 2005 · 61 citations · 34 references
MedicineDermatologyImmunologyImmunopathologyImmunotherapyInflammationAutoimmune Skin DiseasesImmunopathology Of SkinInflammatory DermatosesInflammatory Skin DiseasesInflammatory Skin DisordersCd4 Positive T CellsEpidermal CellsImmunopathological MechanismsPsoriasis ImmunopathologyPsoriasis TherapyPsoriatic DiseaseTumor Necrosis Factor Inhibitor TherapyTumor Necrosis Factor Therapy
BACKGROUND: The pathophysiology of psoriasis is poorly understood, and the mechanism of action of biological agents interfering with tumour necrosis factor (TNF)-alpha that improve psoriatic plaques is completely unknown. OBJECTIVES: To begin to unravel the mechanism of action, cellular changes occurring in plaques following administration of adalimumab, a humanized monoclonal antibody against TNF-alpha, were investigated. METHODS: Thirteen different patients underwent sequential biopsies as part of a clinical trial. Each biopsy was immunostained and evaluated to calculate the relative density of epidermal Langerhans cells (LCs) before and after treatment (days 2, 7, 28, 84). To explore the basis for reduced epidermal LC densities in plaques, a SCID-Hu animal model was utilized. Acute psoriatic lesions were created within 2 weeks by injection of superantigen-activated CD4+ T cells into engrafted symptomless skin. RESULTS: Compared with symptomless skin, untreated plaques had a significantly reduced density of epidermal LCs. There was a rapid increase in density of epidermal LCs in plaques following treatment with adalimumab beginning as early as day 7. The paucity of epidermal LCs in plaques was contrasted to the prominent density of LCs in other skin disorders with chronic inflammation and alterations in keratinization, including lichen planus and inflamed seborrhoeic keratosis. Rapid creation of plaques using the SCID-Hu model was accompanied by loss of epidermal LCs, indicating that diminished LC density occurs at an early stage of lesion formation. CONCLUSIONS: These data shed light on a new immunopathological perspective highlighting a rapid loss of epidermal LCs in acute psoriatic lesions, with sustained decreased density of LCs in chronic plaques. Furthermore, an unexpected insight into the mechanism of action was uncovered for adalimumab, in which rapid restoration of epidermal LC density was observed.
34
Etanercept as Monotherapy in Patients with Psoriasis
Craig L. Leonardi, JEROLD L. POWERS, Robert Matheson et al. · New England Journal of Medicine · 2003 · 1.2K citations · Full text
Langerhans cells renew in the skin throughout life under steady-state conditions
Miriam Mérad, Markus G. Manz, Holger Karsunky et al. · Nature Immunology · 2002 · 937 citations · Full text
Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide
Junichi Hosoi, Gëorge F. Murphy, Christine Egan et al. · Nature · 1993 · 624 citations